Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ).
Zylox-Tonbridge Medical Technology Co., Ltd. held its 2025 annual general meeting in Hangzhou on May 13, 2026, with shareholders or proxies representing about 53.93% of voting share capital in attendance. All directors participated either in person or electronically, and the meeting complied with PRC company law and the firm’s articles of association.
All seven ordinary resolutions put to vote were approved by substantial majorities, including the 2025 board and supervisory committee reports, the audited financial statements, and the 2025 profit distribution plan. Shareholders also backed the reappointment of the external auditor for 2026, authorized the board to set remuneration for directors and senior management, and passed amendments to the 2021 H Share Award and Trust Scheme, affirming existing governance and incentive structures.
The most recent analyst rating on (HK:2190) stock is a Buy with a HK$28.00 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.
More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H
Zylox-Tonbridge Medical Technology Co., Ltd. is a mainland China-based medical technology company listed in Hong Kong. The group focuses on developing and manufacturing medical devices, with its H shares traded on the Stock Exchange of Hong Kong, and maintains both H shares and domestic shares in its capital structure.
Average Trading Volume: 741,252
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.65B
See more data about 2190 stock on TipRanks’ Stock Analysis page.